IRVINE, Calif., Aug. 07, 2017 -- Khang & Khang LLP (the “Firm”) announces the filing of a securities class action lawsuit against Foundation Medicine, Inc. (“Foundation” or the “Company”) (Nasdaq:FMI). Investors who purchased or otherwise acquired shares between February 26, 2014 and November 3, 2015, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the September 26, 2017 lead plaintiff motion deadline.
If you purchased Foundation shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone: (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.
According to the Complaint, throughout the Class Period, Foundation made false and/or misleading statements, and/or failed to disclose, material information to investors. On July 29, 2015, the Company announced that it was not making the strides obtaining coverage it claimed to have been making during the Class Period, and that Foundation would receive no Medicare payments in 2015 for its tumor profiling tests due to a delay in receiving a local coverage determination from its regional Medicare Administrative Contractor. As a result of the delay, the Company cut its 2015 financial guidance, which was based on an assumption that Medicare approval was going to be obtained in 2015. On this news, Foundation’s stock price dropped significantly. On November 3, 2015, the Company revealed another revision to the already reduced number of clinical tests it expected to report for 2015. When this news reached the public, shares of Foundation declined in value materially, causing investors harm according to the Complaint.
If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at [email protected].
This press release may constitute Attorney Advertising in some jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]


TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Anta Sports Expands Global Footprint With Strategic Puma Stake
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 



